Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.